Growing Young: The Longevity Revolution

How the Anti-aging Field is Shaping The Human Existence

Program

Growing old is a fact of life for all living creatures. Humans have been fighting the signs and symptoms of aging for decades; with scientists focused on finding new ways to cosmetically prevent the physical effects of aging and to develop treatments for age-related diseases and conditions.

With the emerging field of anti-aging, research is now looking further upstream to focus on the root cause of aging and to leverage new and innovative technology in an effort to turn back the clock on age-related diseases. The goal of extending life expectancy—or at least allowing humans to live healthier into old age—has already garnered the attention of several tech billionaires including Jeff Bezos and Peter Thiel. As a result, start-ups in this space are popping up more frequently and attracting interest from VCs.

Panel

Join us to explore the emerging field of anti-aging and the revolutionary technologies employed to both understand and address the aging process. We’ll hear from industry experts, start-ups and investors on what is driving innovation, the opportunities for biotech start-ups, the investment trends shaping the sector and how lifespan technology can successfully fit into a biotech model designed with a limited window of time for investment. We’ll also discuss ethical implications and societal impacts surrounding anti-aging interventions.

Speakers

Dan Oliver, MBA, CEO & Co-Founder, Rejuvenate Bio
Daniel Oliver is a co-founder and the CEO of Rejuvenate Bio, a startup out of George Church’s Lab at Harvard Medical School. Prior to Rejuvenate Bio, Daniel was awarded a Blavatnik Fellowship during which he co-founded Voxel8. Voxel8 was named one of the top 9 innovations at CES and one of the top 50 most innovative companies by the MIT Technology Review. Daniel received his MBA from Harvard Business School and has degrees in Mechanical Engineering and Business from the California Institute of Technology.
Anthony J.A. Molina, PhD, Professor & Scientific Director, Stein Institute for Research on Aging & UCSD Center for Healthy Aging
Anthony Molina, PhD, is a Professor of Medicine at UC San Diego and serves as the Research Chief in the Division of Geriatrics, Gerontology, and Palliative Care. Dr. Molina is the Scientific Director for the Sam and Rose Stein Institute for Research on Aging and the UC San Diego Center for Healthy Aging. The overarching goal of Dr. Molina’s research is to promote healthy aging and to advance precision healthcare for older adults. His team is leading efforts to: 1) understand the multi-faceted factors influencing the cognitive and physical abilities of older adults, 2) develop improved diagnostic and prognostic tools for age-related diseases and disorders, and 3) identify strategies for promoting healthy longevity.
David Crean, PhD, MBA, Managing Partner, Cardiff Advisory
David H. Crean, Ph.D. has carved a distinguished career over three decades, excelling in mergers & acquisitions, strategic partnerships, and investments across the life sciences and healthcare industries. His expertise spans executive roles within biopharmaceutical companies, investment banking, private equity, and venture capital. At the helm of Cardiff Advisory LLC as a Managing Partner, Dr. Crean specializes in mergers and acquisitions (M&A), corporate partnering, valuations, and strategic advisory services, focusing on the life science and healthcare sectors.
Alex Aravanis, PhD, MD, CEO & Co-Founder Moonwalk Biosciences
Alex Aravanis is CEO and co-founder of Moonwalk Biosciences, Inc. Prior to Moonwalk, Alex was Illumina’s Chief Technology Officer, SVP, and Head of Research and Product Development. Under his leadership, Illumina launched the industry’s leading products for genomics-based research and clinical applications, including whole genome sequencing, comprehensive genomic profiling of cancer, COVID-Seq, and the most advanced AI tools for interpreting genomic information. Alex is an experienced entrepreneur and was involved in founding several start-ups in life sciences. Most recently, he co-founded GRAIL Bio where he served as Chief Scientific Officer and Head of R&D.
Rubén Darío Flores Saaib, PhD, Interim Chief Executive Officer, Regain BioMedicals
As the Academic and Corporate Business Development Lead at General Inception, Rubén leans on his 20+ years of experience in bridging the gap between academia and industry, and turning cutting-edge research into novel and impactful products and services. His mission is to partner with inventors, entrepreneurs, and investors to ignite innovation and create transformational companies benefiting society and our planet. Rubén also serves as the Interim Chief Executive Officer at Regain BioMedicals, a startup developing a novel device to treat essential tremor, a debilitating condition that affects millions of people worldwide.